Trispecific Antibodies Excel in Trials, Garner Pharma Interest

Shortly after positive data were announced, AbbVie recently struck a deal with Ichnos Glenmark Innovation to acquire ISB 2001, a trispecific T-cell engager for multiple myeloma, the latest sign of the pharmaceutical industry’s interest in developing these agents. Patients taking JNJ-5322, a trispecific antibody from Johnson & Johnson to treat the disease, also experienced high response rates in a recently reported phase I study.

Publication Details

Journal
Cancer Discovery
Published
2025-01-01
DOI
https://doi.org/10.1158/2159-8290.cd-nw2025-0061
Primary Topic
Monoclonal and Polyclonal Antibodies Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Trispecific Antibodies Excel in Trials, Garner Pharma Interest

Cancer Discovery
Monoclonal and Polyclonal Antibodies Research
article

Trispecific Antibodies Excel in Trials, Garner Pharma Interest

article en

Abstract

Shortly after positive data were announced, AbbVie recently struck a deal with Ichnos Glenmark Innovation to acquire ISB 2001, a trispecific T-cell engager for multiple myeloma, the latest sign of the pharmaceutical industry’s interest in developing these agents. Patients taking JNJ-5322, a trispecific antibody from Johnson & Johnson to treat the disease, also experienced high response rates in a recently reported phase I study.

Cancer Discovery
Openalex Percentile: Top 73%
Monoclonal and Polyclonal Antibodies Research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Trispecific Antibodies Excel in Trials, Garner Pharma Interest · Cancer Discovery (2025) | TGRS Research Map | TGRS